bms-986235
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 14, 2017 (NCT03335553)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- fMet-Leu-Phe receptor 1/2AGONIST
fMet-Leu-Phe receptor 1/2 agonist
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc(F)c([C@@H]2CNC(=O)[C@H]2NC(=O)Nc2ccccc2)c(F)c1- Mol. weight
- 361.35 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4784510 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04464577 | Phase 1 | Apr 1, 2021 | Bristol-Myers Squibb |
| NCT04301310 | Phase 1 | May 15, 2020 | Bristol-Myers Squibb |
| NCT03335553 | Phase 1 | Nov 14, 2017 | Bristol-Myers Squibb |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 3 | 3 | 1 | 2017 |
1 organizations
Page 1 / 1